TY - JOUR
T1 - Persistence of antimuscarinic drug use
AU - Brostrøm, Søren
AU - Hallas, Jesper
N1 - Keywords: Aged; Databases, Factual; Denmark; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Nortropanes; Patient Compliance; Quality of Life; Urinary Bladder, Overactive
PY - 2009
Y1 - 2009
N2 - PURPOSE: Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies. METHODS: All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999-2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination. RESULTS: With the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years. CONCLUSIONS: In a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.
AB - PURPOSE: Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies. METHODS: All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999-2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination. RESULTS: With the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years. CONCLUSIONS: In a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.
U2 - 10.1007/s00228-008-0600-9
DO - 10.1007/s00228-008-0600-9
M3 - Journal article
C2 - 19107469
VL - 65
SP - 309
EP - 314
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
SN - 0031-6970
IS - 3
ER -